Blog

Matthew Kurian: Highlights from Day 1 at ASCO25’s Metastatic Breast Cancer Data that stood out

Matthew Kurian/youtube.com

Jun 1, 2025, 10:03

Matthew Kurian: Highlights from Day 1 at ASCO25’s Metastatic Breast Cancer Data that stood out

Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine, shared a post on LinkedIn:

“Day 1 at ASCO25 — What a start!

Yesterday, I was grateful and energized to kick off the meeting with a full slate of panel discussions, meaningful conversations, and insightful sessions.

Honored to bring the voice of the community oncologist to the table — while also representing as a subspecialist in breast and GU cancers. Bridging academic innovation with real-world practice is more than a talking point in the community it affects everyday lives.

Highlights from yesterday’s metastatic breast cancer data that stood out:

T-DXd re-challenge in a diverse, real-world population (Hope Rugo)

– Rechallenge after Grade 1 ILD showed no Grade 5 ILD events.

– Median time to ILD: 5 months | Median duration on therapy: 215 days.

– 61% had dose reductions, yet clinical benefit maintained.

– A reminder: CT chest at 6 weeks, no longer than 9 weeks

OPTI-TROP5 (Sacituzumab Tirumotecan):

– Novel Trop-2–directed ADC with a belotecan-based topoisomerase I inhibitor payload.

– In mTNBC (PD-L1–agnostic): ORR 45.4%, DCR 92%.

– Median PFS: 6.7 mo vs 2.5 mo (HR 0.32) | OS not reached vs 9.4 mo (HR 0.53).

– Unique AEs: Cytopenias, stomatitis (10%), and rare but notable exophthalmia & blurred vision (3.1%).

– Manageable toxicity with promising durability and activity in a challenging population.

– Question: How does it stack up against sacituzumab govitecan in this setting?

KAT6 inhibitor + fulvestrant (Patricia LoRusso, Yale Cancer Center):

– First-in-class, novel KAT6 inhibitor (PF-07248144) in Phase I dose escalation/expansion.

– In ER+/HER2– MBC post-CDK4/6, combination showed:

→ ORR 37.2%, median PFS 10.7 months.

– Safety: Dysgeusia (84.6%, mostly Grade 1); Grade ≥3 neutropenia ~37%.

– Question: Where does this fit in with new oral SERDs?

From hallway chats to clinical deep-dives, the spirit of collaboration and shared purpose was everywhere. Whether you’re at a major academic center or, like me, in a community setting — we’re all pushing oncology forward, together.

Let’s keep the momentum going! If we met today — let’s keep in touch. If we haven’t yet — come find me!”

Kurian reflected on Day 1 of ASCO25, focusing on new clinical findings in metastatic breast cancer, including data on T-DXd re-challenge, OPTI-TROP5, and a KAT6 inhibitor plus fulvestrant combination.

More posts featuring Matthew Kurian.

ADC ASCO25 belotecan Breast Cancer cancer cytopenias Dysgeusia fight against cancer Global fight against cancer Grade 1 ILD GU cancers HER2 Hope Rugo KAT6 inhibitor Matthew Kurian neutropenia OncoDaily Oncology OPTI-TROP5 Patricia LoRusso PD-L1–agnostic Sacituzumab Tirumotecan SERDs stomatitis T-Dxd topoisomerase University of Kentucky College of Medicine Yale Cancer Center

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment

15 Posts Not to Miss from the 2nd Day of ASCO 2025

15 Posts Not to Miss from the 1st Day of ASCO 2025

Wafik El-Deiry: Inside Yvonne Award Ceremony 2025